Hexahydrofarnesyl as an original bio-sourced alkyl chain for the preparation of glycosides surfactants with enhanced physicochemical properties

International audienceFive new bio-based surfactants have been synthetized by coupling hexahydrofarnesol with mono and di-saccharides. Hexahydrofarnesol (3,7,11-trimethyl-dodecan-1-ol) is a by-product of the industrial production of farnesane, a sustainable aviation fuel obtained by a fermentation process from sugar feedstocks. Using hexahydrofarnesol as the lipophilic starting material allows obtaining 100% bio-based surfactants while valorizing an industrial by-product. Moreover, the C15-branched alkyl chain brings unique properties to the surfactants. This paper presents a physicochemical characterization of these new surfactants including their behaviors in water (water solubility, critical micellar concentration and surface tension) and in oil/water systems (interfacial tension against model oil and ternary phase behavior). Their hydrophilicities have been determined thanks to the PIT-slope method and compared to the ones of standard surfactants with linear alkyl chains, in order to distinguish the contributions of the sugar polar heads and of the branched hexahydrofarnesyl lipophilic chain. This novel class of surfactants combines the properties of sugar-based surfactants (low sensitivity to temperature and salinity, ability to form Winsor III microemulsion systems over a wide range of salinity), along with specificities linked to the branched alkyl chain (lower Krafft temperature, low surface tension)

Spitz tumor with RAF1 fusion : a report of 3 cases

Spitz tumors are melanocytic neoplasms morphologically characterized by spindled and/or epithelioid cells and specific stromal and epidermal changes associated with mutually exclusive fusion kinases involving ALK, ROS1, NTRK1, NTRK2, NTRK3, MET and RET, BRAF and MAP3K8 genes or, less commonly, HRAS mutation. RAF1 fusions have been recently detected in cutaneous melanocytic neoplasms, including conventional melanoma, congenital nevus and BAP-1 inactivated tumors. We report herewith three Spitz neoplasms with a RAF1 fusion, including a previously reported CTDSPL::RAF1 fusion and two novel PPAP2B::RAF1 and ATP2B4::RAF1 fusions. Two cases were classified as Spitz nevus, while the remaining neoplasm was classified as Spitz melanoma at the time of the diagnosis, given 9p21 homozygous deletion and positive sentinel lymph node biopsy. We suggest that RAF1 fused melanocytic neoplasms can represent a novel subgroup of Spitz tumors, with a RAF1 fusion representing an oncogenic driver

Fractional Flow Reserve to Guide Treatment of Patients With Multivessel Coronary Artery Disease

International audienc